Congratulations! The Professor Tzu-Ming Pan from National Taiwan University is awarded the Industry-University Collaboration Award in 2010.
SunWay 2020 annual revenue was 314 million and will be listed on Taiwan Emerging Stock Market on January 18, 2021.
On January 12, SunWay Biotech Co., LTD. (1271) was invited by Fubon Securities Co., Ltd. to participate in the institutional investor conference. John Pan, President of SunWay Biotech, introduced two main ingredients-ANKASCIN 568-R and Vigiis 101-LAB probiotics and their application, and announced that SunWay Biotech will be listed on Taiwan Emerging Stock Market on January 18, 2021.
Interview from PharmaBoardRoom: George J. Lee, Ph.D. – Chairman; Tzu-Ming Pan, Ph.D – Vice Chairman and Chief Technology and Science Officer, SunWay Biotech, Taiwan
George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the same compounds.
We sincerely invite you to join us in the SunWay Biotech Presentation of BIO Asia-Taiwan. Please register for Free Admission to On-demand Company Presentations of BIO Asia-Taiwan during July 21-25. After registration, please click Session and then type cp31 or SunWay to join our Company Presentation and know more about our service. Register Now: https://bit.ly/3xFl57D